Alnylam Pharmaceuticals Inc. (ALNY) News
Filter ALNY News Items
ALNY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ALNY News Highlights
- For ALNY, its 30 day story count is now at 5.
- Over the past 16 days, the trend for ALNY's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest ALNY News From Around the Web
Below are the latest news stories about ALNYLAM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ALNY as an investment opportunity.
Ionis, Astrazeneca win FDA approval of competitor to Alnylam drugThe clearance of Wainua for transthyretin amyloidosis opens up a new front in a long-running commercial battle between Ionis and Alnylam. |
13 Most Promising Healthcare Stocks According to AnalystsIn this article, we discuss the 13 most promising healthcare stocks according to analysts. To skip the detailed overview of the healthcare sector, go directly to the 5 Most Promising Healthcare Stocks According to Analysts. The healthcare industry landscape is changing. While the COVID-19 pandemic was one of the most significant events that led to […] |
Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D DayCAMBRIDGE, Mass., December 13, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting a virtual R&D Day today. During the event, the Company plans to showcase its R&D progress and platform innovation, as well as its product and pipeline goals for 2024, including continued commercial execution of four RNAi therapeutic products and the advancement of early-, mid-, and late-stage investigational programs. |
Alnylam to Webcast Virtual R&D DayCAMBRIDGE, Mass., December 06, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company’s website, www.alnylam.com, on Wednesday, December 13, 2023 at 8:30 am ET. A replay will be available on the Alnylam website within 48 hours after the event. |
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023CAMBRIDGE, Mass., November 30, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its first-place ranking in Boston Globe’s 2023 Top Places to Work in the "Largest Employer" category. This marks the third year in a row that Alnylam has taken the top spot in the Largest Employer category (> 1,000 employees). |
Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular RiskCAMBRIDGE, Mass., November 11, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive results from the KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of patients with hypertension and high cardiovascular risk. The study results were presented during the American Heart Association (AHA) Scientific Sessions being held in Philadelp |
Wall Street Analysts Think Alnylam (ALNY) Could Surge 35.08%: Read This Before Placing a BetThe average of price targets set by Wall Street analysts indicates a potential upside of 35.1% in Alnylam (ALNY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Alnylam to Webcast Presentations at Upcoming November Investor ConferencesCAMBRIDGE, Mass., November 07, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: |
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2023 Earnings Call TranscriptAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2023 Earnings Call Transcript November 2, 2023 Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $1.15, expectations were $-1.61. Operator: Good day and thank you for standing by. Welcome to the Alnylam Pharmaceuticals Q3 2023 Earnings Conference Call. At this time, participants are in a listen-only mode. After the […] |
Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration RevenuesAlnylam (ALNY) reports better-than-expected third-quarter 2023 results, beating both earnings and sales estimates on the back of higher collaboration revenues. |